Abstract
Calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, CMA-676, has recently been introduced to clinics as a promising drug to treat patients with acute myeloid leukemia (AML) in relapse. However, the mechanism of action of CMA-676 has not been well elucidated. The cytotoxic effect of CMA-676 on HL60, NOMO-1, NB4, NKM-1, K562, Daudi, and the multidrug-resistant sublines, NOMO-1/ADR and NB4/MDR, was investigated by cell cycle distribution and morphology. These studies were done by a video-microscopic system, DNA fragmentation, dye exclusion and 3H-thymidine uptake after analysis of CD33, CD34, P-glycoprotein (P-gp), multidrug resistance (MDR)-associated protein and lung-related protein on these cells. A dose-dependent, selective cytotoxic effect of CMA-676 was observed in cell lines that expressed CD33, and was dependent on the amount of CD33 and the proliferative speed of the cells. Sensitive cells were temporally arrested at the G2/M phase before undergoing morphological changes. CMA-676 is not effective on P-gp-expressing multidrug-resistant sublines compared with parental cell lines. MDR modifiers, MS209 and PSC833, restored the cytotoxic effect of CMA-676 in P-gp-expressing sublines. CMA-676 is a promising agent in the treatment of patients with AML that expresses CD33. The combined use of CMA-676 and MDR modifiers may increase the selective cytotoxic effect in multidrug-resistant AML.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Marie J . P-glycoprotein in Adult Hematologic Malignancies Saunders: Philadelphia, PA 1995
List AF . The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia Leukemia 1996 10: S36–S38
Willman CL . The prognostic significance of the expression and function of multidrug-resistance transporter proteins in acute myeloid leukemia: studies of Southwest Oncology Group Leukemia Research Program Semin Hematol 1997 34: 25–33
Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Hatake K, Kuriyama K, Ohmoto E, Saito K, Kanamaru A, Oho H, Ohtake S, Jinnai I, Sakamaki H, Yamada O, Asou N, Takahashi M, Takeyama K, Matsuda S, Ueda R, Ohno R . Randomized study of individualized induction therapy with or without etoposide in adult acute myeloid leukemia (except for M3) (JALSG-AML92 study) and analysis of prognostic factors Blood 1997 90: (Suppl. 1) 503a (Abstr.)
Takeshita A, Shinjo K, Naito K, Fujisawa S, Shigeno K, Ohnishi K, Naoe T, Ohno R . No role of P-glycoprotein (P-gp) to all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukemia (APL) cells: analysis of P-gp and intra-cellular concentration of ATRA Blood 1998 92: (Suppl. 1) 597a (Abstr.)
Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A, Karasuno T, Takeuchi M, Miyawaki S, Ueda R, Naoe T, Ohno R . Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid Blood 1997 90: 967–973
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients Blood 1997 89: 3354–3360
Multani PS, Grossbard ML . Monoclonal antibody-based therapies for hematologic malignancies J Clin Oncol 1998 16: 3691–3710
Buchsbaum DJ, Lawrence TS . Tumor therapy with radiolabeled monoclonal antibodies Antibody Immunocon Radiopharm 1991 4: 245–272
Fritzberg AR, Baumier PL, Bottino BJ, Reno JM . Approaches to improved antibody- and peptide-mediated targeting for imaging and thrapy of cancer J Control Release 1994 28: 167–173
Bagshawe KD . Antibody-directed enzyme prodrug therapy (ADEPT) J Control Release 1994 28: 187–193
Brinkmann U, Pastan I . Immunotoxins against cancer Biochim Biophys Acta 1994 1198: 27–45
Freeman SD, Kelm S, Barber EK, Crocker PR . Characterization of CD33 as a new member of the sialoadesin family of cellular interaction molecules Blood 1995 85: 2005–2012
Wagner JE, Collins D, Fuller S, Schain LR, Berson AE, Almici C, Hall MA, Chen KE, Okarma TB, Lebkowski JS . Isolation of small, primitive human hematopoietic stem cells: distribution of cell surface cytokine receptors and growth in SCID-Hu mice Blood 1995 86: 512–523
Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID . Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 1999 93: 3678–3684
Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ . Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias J Clin Oncol 1993 11: 294–303
Jurcic JG, Philip CC, Nikura TK, Paradopoulos EB, Finn RD, Gansow OA, Miller WHJr, Geerlings MW, Warrell RPJr, Larson SM, Scheinberg DA . Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias Cancer Res 1995 55: 5908s–5910s
Juric JG, Deblasio A, Dumont L, Warrell RPJr, Scheinberg DA . Molecular remission induction without relapse after anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia (APL) Blood 1997 90: (Suppl. 1) 416a (Abstr.)
Juric JG, McDevitt MR, Sgooros G, Ballangrud A, Finn RD, Geerlings MW, Humm JL, Molinet R, Apostolidis C, Larson SM, Scheinberg DA . Targeted alpha-particle thrapy for myeloid leukemias: a phase I trial of bismuth-213-HuM195 (anti-CD33) Blood 1997 90: (Suppl. 1) 504a (Abstr.)
Pagliaro LC, Liu B, Munker R, Andreeff M, Freireich EJ, Scheinberg DA, Rosenblum MG . Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity Clin Cancer Res 1998 4: 1971–1976
Roy DC, Griffin JD, Belvin M, Blattler WA, Lambert JM, Ritz J . Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells Blood 1991 77: 2404–2412
Lee MD, Dunne TS, Siegel MM, Chang CC, Morton GO, Borders DB . Calicheamicins, a novel family of antitumor antibiotics. 1: Chemistry and partial structure of calicheamicin γ1I J Am Chem Soc 1987 109: 3464–3466
Lee MD, Dunne TS, Chang CC, Ellestad GA, Siegel MM, Morton GO, McGahren WJ, Borders DB . Calicheamicins, a novel family of antitumor antibiotics. 2: Chemistry and structure of calicheamicin γ1I J Am Chem Soc 1987 109: 3466–3468
Zein N, Poncin M, Nilakantan R, Ellestad GA . Calicheamicin γ1I and DNA: molecular recognition process responsible for site-specificity Science 1989 244: 697–699
Hangeland JJ, De Voss JJ, Heath JA, Townsend CA . Specific abstraction of the 5′ (S)- and 4′-deoxyribosyl hydrogen atoms from DNA by calicheamicin γ1I J Am Chem Soc 1992 114: 9200–9202
Sievers EL, Larson RA, Estey E, Stadtmauer E, Berger M, Eten C, Bernstein I, Applebaum F . Interim analysis of the efficacy and safety of CMA-676 in patients with AML in first relapse Blood 1998 92: (Suppl. 1) 613a (Abstr.)
Nicolaou KC, Li T, Nakada M, Hummel CW, Hiatt A, Wrasidlo W . Calicheamicin θI1: a rationally designed molecule with extremely potent and selective DNA cleaving properties and apoptosis inducing activity Angew Chem Int Ed Engl 1994 33: 183–186
Zhao B, Konno S, Wu JM, Oronsky AL . Modulation of nicotinamide adenine dinucleotide and poly (adenocine diphosphoribose) metabolism by calicheamicin γ1 in human HL-60 cells Cancer Lett 1990 50: 141–147
Tsuruo T, Saito H, Kawabata H, Ohhara T, Hamada H, Utakoji T . Characteristics of resistance to Adriamycin in human myelogenous leukemia K562 resistant to Adriamycin and in isolated clones Jpn J Cancer Res 1986 77: 682–692
Hamaguchi M, Morishita Y, Takahashi I, Ogura M, Takamatsu J, Saito H . FDP D-dimer induces the serection of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in human promyelocytic leukemia cell line Blood 1991 77: 94–100
Takeshita A, Shinjo K, Ohnishi K, Ohno R . New flow cytometric method for detection of minimally expressed multidrug resistance P-glycoprotein on normal and acute leukemia cells using biotinylated MRK16 and streptavidin-RED670 conjugate Jpn J Cancer Res 1995 86: 607–615
Takeshita A, Shinjo K, Ohnishi K, Ohno R . Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukemia cells Br J Haematol 1996 93: 18–21
Den Boer ML, Zwaan CM, Pieters R, Kazemier KM, Rottier MM, Flens MJ, Scheper RJ, Veerman AJ . Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia Leukemia 1997 11: 1078–1085
Overton WR . Modified histogram subtraction technique for analysis of flow cytometry data Cytometry 1998 9: 619–626
Muller MR, Lennartz K, Nowrousian MR, Dux R, Tsuruo T, Rajewsky MF, Seeber S . Improved flow-cytometric detection of lowP-glycoprotein expression in leukaemic blasts by histogram subtraction analysis Cytometry 1994 15: 64–72
Terakawa S, Fan JH, Kumakura K, Ohara-Imaizumi M . Quantitative analysis of exocytosis directly visualized in living chromaffin cells Neurosci Lett 1991 11: 82–86
Sellins KS, Cohen JJ . Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes J Immunol 1987 139: 3199–3206
Kartner N, Evernden-Porelle D, Bradley G, Ling V . Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies Nature 1985 316: 820–823
Gottesman MM, Pastan I, Ambudkar SV . P-glycoprotein and multidrug resistance Curr Opin Genet Dev 1996 6: 610–617
Baba M, Nakanishi O, Sato W, Saito A, Miyama Y, Yano O, Shimada S, Fukazawa N, Naito M, Tsuruo T . Relationship between multidrug resistant gene expression and multidrug resistant-reversing effect of MS-209 in various tumor cells Cancer Chemother Pharmacol 1995 36: 361–367
Friche E, Jensen PB, Nissen NI . Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor Cancer Chemother Pharmacol 1992 30: 235–237
Acknowledgements
We would like to express our sincere gratitude to Ms Yoshimi Suzuki, Ms Noriko Anma, Ms Naoko Sugiura, and Ms Keiko Natsume for technical assistance and to Dr Kiyoshi Shibata (Equipment Centre, Hamamatsu University School of Medicine) for his co-operation. We are indebted to Wyeth-Ayerst Research Division of American Home Products for supply of test substances.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Naito, K., Takeshita, A., Shigeno, K. et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 14, 1436–1443 (2000). https://doi.org/10.1038/sj.leu.2401851
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401851
Keywords
This article is cited by
-
A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype
Cancer Chemotherapy and Pharmacology (2023)
-
Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy
Current Oncology Reports (2021)
-
Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies
Current Hematologic Malignancy Reports (2018)
-
Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia
International Journal of Hematology (2013)